Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05450848
Other study ID # SPASX01AU002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2017
Est. completion date March 31, 2023

Study information

Verified date July 2023
Source Stratpharma AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Current clinical practice for preventing and treating radiation dermatitis across Queensland (QLD) Health Radiation Oncology departments involves the application of aqueous cream daily to the skin of the treatment site, commencing from Day 1 of EBRT. The primary aim of this study is to assess the efficacy of StrataXRT when compared to current clinical practice in preventing and managing radiation dermatitis.


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date March 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with cancer undergoing a curative course of radiation therapy using standard protocols to the following cancer sites: - Head and neck cancers receiving >= 60Gy who are not receiving concurrent Cetuximab - Intact breast receiving >= 40Gy (includes patients receiving boost fields using photon or elections) - Post-mastectomy chest wall (breast cancer diagnosis only) receiving >= 50Gy - Gynaecological cancers requiring whole pelvis irradiation receiving >= 45Gy - Skin cancers to the axilla/groin regions receiving >= 40Gy - Male and female patients >18 years of age - Patients who do not have a known allergy to silicon - Patients who are able to attend the four post-treatment weekly skin assessment appointments Exclusion Criteria: Ineligible participants are patients undergoing a course of curative radiation therapy: - Who are participating in another interventional study - With an allergy to product content (standard or StrataXRT) - With an existing skin rash, ulceration or open wound in the treatment area - With a pre-existing systemic skin disease (dermatological conditions, connective tissue disorders) - Who have had previous radiation therapy to the current treatment area - Who are on immuno-suppression drugs

Study Design


Related Conditions & MeSH terms


Intervention

Device:
StrataXRT
StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
Other:
Sorbolene
Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.

Locations

Country Name City State
Australia Townsville Cancer Center, Townsville Hospital and Health Service Douglas Queensland
Australia Princess Alexandra Hospital South Brisbane Queensland

Sponsors (1)

Lead Sponsor Collaborator
Stratpharma AG

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Radiation dermatitis reaction as assessed by blinded assessment of digital photographs using the CTCAE v4.0 radiation dermatitis grades. CTCAE v4.0 severity grades are categorical with 5 possible categories (1, 2, 3, 4, 5). Grade 1 represents the weakest form of radiation dermatitis. Higher CTCAE Grades represent increasing radiation dermatitis severity. From radiotherapy start, until to 4 weeks post radiation therapy; up to 3 months
Primary Radiation induced skin reaction assessment scale (RISRAS) Radiation dermatitis reaction as assessed by the clinician during patient consultations using the eviQ RISRAS form. RISRAS scale is continuous scale from 0 to 36, with higher RISRAS scores representing higher severity of radiation dermatitis. From radiotherapy start, until to 4 weeks post radiation therapy; up to 3 months
Secondary Onset of radiation dermatitis Timepoint of onset of CTCAE v4.0 radiation dermatitis Grades 2 and/or 3 during or after radiotherapy. From radiotherapy start, until to 4 weeks post radiation therapy; up to 3 months
Secondary Length of time until resolution of radiation dermatitis Length of time from peak incidence to resolution of radiation dermatitis. From onset of radiation dermatitis, until radiation dermatitis resolution, up to 3 months
Secondary Patient reported symptoms treatment Patient reported comfort scale obtained using the eviQ RISRAS form. From onset of radiation dermatitis, until radiation dermatitis resolution, up to 3 months
Secondary Cost-effectiveness The mean total cost of skin care per patient. From radiotherapy start, until to 4 weeks post radiation therapy; up to 3 months
Secondary Incidence of late-effects skin toxicity The late skin toxicity post-radiotherapy assessed using the Radiation Therapy Oncology Group (RTOG) grading definitions:
Grade 0: No change over baseline Grade I: Follicular, faint or dull erythema, epilation, dry desquamation, decreased sweating Grade II: Tender or bright erythema, patchy moist desquamation, moderate oedema Grade III: Confluent, moist desquamation other than skin folds, pitting oedema Grade IV: Ulceration haemorrhage, necrosis
3 - 12 months post radiation treatment
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Not yet recruiting NCT06040983 - Clinical Investigation on the Treatment of Radiation Induced Dermatitis With FR-101 Chest Dressing N/A
Withdrawn NCT05505214 - Topical Steroids & Bacterial Decolonization for Radiation Dermatitis Phase 2
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Active, not recruiting NCT05594498 - A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients N/A
Recruiting NCT04110977 - A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer N/A
Recruiting NCT06158347 - Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients With Localized Breast Cancer N/A
Recruiting NCT05553392 - StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis N/A
Active, not recruiting NCT04268056 - Characterization of Skin Microbiome Profile and it's Correlation to Radiation Dermatitis
Not yet recruiting NCT04888234 - Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis. Phase 2
Terminated NCT01597921 - A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer N/A
Completed NCT00481884 - Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients Phase 3
Completed NCT03494205 - Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis Phase 2
Completed NCT05810194 - Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis
Completed NCT03941665 - Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients N/A
Not yet recruiting NCT02051907 - Clinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis Phase 2
Completed NCT02839473 - Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial Phase 3
Completed NCT00573365 - LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis N/A
Completed NCT00876642 - Trial Comparing Best Supportive Care to Aloe Vera Gel Phase 3
Completed NCT03910595 - Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients N/A